Galactan biosynthesis in Mycobacterium tuberculosis -: Identification of a bifunctional UDP-galactofuranosyltransferase
Galactan biosynthesis in Mycobacterium tuberculosis -: Identification of a bifunctional UDP-galactofuranosyltransferase
复制标题
DOI：
10.1074/jbc.m102022200
复制
发表时间：
2001-07-13
影响因子：
4.8
通讯作者：
Besra, GS
中科院分区：
文献类型：
--
作者：
Kremer, L;Dover, LG;Besra, GS
The cell wall of Mycobacterium tuberculosis and related genera is unique among prokaryotes, consisting of a covalently bound complex of mycolic acids, D-arabinan and D-galactan, which is linked to peptidoglycan via a special linkage unit consisting of Rhap-(1 -->3)-GlcNAc-P. Information concerning the biosynthesis of this entire polymer is now emerging with the promise of new drug targets against tuberculosis. Accordingly, we have developed a galactosyltransferase assay that utilizes the disaccharide neoglycolipid accepters beta -D-Galf-(1 -->5)-beta -Galf-O-C-10:1 and beta -D-Galf-(1 -->6)-beta -D-Galf-O-C-10:1, with UDP-Gal in conjunction with isolated membranes. Chemical analysis of the subsequent reaction products established that the enzymatically synthesized products contained both beta -D-Galf linkages ((1 -->5) and (1 -->6)) found within the mycobacterial cell, as well as in an alternating (1 -->5) and (1 -->6) fashion consistent with the established structure of the cell wall. Furthermore, through a detailed examination of the M. tuberculosis genome, we have shown that the gene product of Rv3808c, now termed glfT is a novel UDP-galactofuranosyltransferase, This enzyme possesses dual functionality in per forming both (1 -->5) and (1 -->6) galactofuranosyltransferase reactions with the above neoglycolipid accepters, using membranes isolated from the heterologous host Escherichia coli expressing Rv3808c, Thus, at a biochemical and genetic level, the polymerization of the galactan region of the mycolyl-arabinogalactan complex has been defined, allowing the possibility of further studies toward substrate recognition and catalysis and assay development. Ultimately, this may also lead to a more rational approach to drug design to be explored in the context of mycobacterial infections.
